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C-terminal mutations of CD20 constitute part of the mechan-
isms that resist rituximab therapy. Most CD20 having a
C-terminal mutation was not recognized by L26 antibody. As
the exact epitope of L26 has not been determined, expression
and localization of mutated CD20 have not been completely
elucidated. In this study, we revealed that the binding site of
L26 monoclonal antibody is located in the C-terminal cytoplas-
mic region of CD20 molecule, which was often lost in mutated
CD20 molecules. This indicates that it is difﬁcult to distinguish
the mutation of CD20 from under expression of the CD20
protein. To detect comprehensive CD20 molecules including
the resistant mutants, we developed a novel monoclonal
antibody that recognizes the N-terminal cytoplasm region of
CD20 molecule. We screened L26-negative cases with our
antibody and found several mutations. A rituximab-binding
analysis using the cryopreserved specimen that mutation was
identiﬁed in CD20 molecules indicated that the C-terminal
region of CD20 undertakes a critical role in presentation of the
large loop in which the rituximab-binding site locates. Thus,
combination of antibodies of two kinds of epitope permits the
identiﬁcation of C-terminal CD20 mutations associated with
irreversible resistance to rituximab and may help the decision
of the treatment strategy.
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Introduction
Previously, we reported that gene mutations of CD20 were
somehow involved in resistance to rituximab therapy, and we
proposed that C-terminal deletion mutations of CD20 might be
related to relapse/resistance after rituximab therapy.
1 Many of
these C-terminal truncated CD20 molecules were not recog-
nized by the L26 monoclonal antibody used routinely in most
clinical laboratories. Therefore, expression of CD20 seemed to
have been completely lost for these lymphomas. However, an
immunohistochemical study using a polyclonal antibody
showed that some kind of C-terminal truncated CD20 was
present in cytoplasm, so it was possible that the epitope of L26
was lost by gene mutations.
1 L26 recognizes the cytoplasmic
region of CD20 molecules, but no more detailed information
about its epitope had been reported.
2,3 In this study, we
determine a recognition site of L26 by using a series of deletion
mutants of CD20 molecules. In addition, to detect every one of
the mutated CD20 molecules, we developed new antibodies
that recognize the N-terminal region of CD20 molecules. We
used these antibodies to identify cells that have CD20 molecules
with abnormalities in the C-terminal cytoplasmic region. We
characterized these mutated CD20 molecules using living
primary lymphoma cells.
Materials and methods
Cells, viruses and DNA constructs
The coding region of the CD20 gene was ampliﬁed by reverse
transcription PCR (RT-PCR) from RNA extracted from a Burkitt’s
lymphoma cell line, Raji, and was cloned into a pDON-AI
retroviral vector (Takara, Ohtsu, Japan). A series of deletion
mutants of CD20 in the C-terminal cytoplasmic region was
constructed by inserting stop codons after nucleotides encoding
E281, E263, E245, V228 and G210. Retroviruses carrying wild
type and deletion mutants of CD20, together with mock
construct, were produced with the transient retrovirus packaging
cell line G3T-hi (Takara) according to the manufacturer’s
protocol. Packaged retrovirus vectors were then used to infect
a myeloma cell line, KMS12PE,
4 with subsequent selection
using 500mg/ml G418.
For the transfection of mutant CD20 gene, whole coding
region of CD20 complementary DNA (cDNA) prepared by
RT-PCR of total RNA isolated from the patient cells was cloned
into ﬁrst cassette of a bicistronic retrovirus vector carrying a
green ﬂuorescent protein (Takara). Bicistronic expression of
ZsGreen is facilitated by internal ribosomal entry site only when
CD20 mutant gene was translated, enabling the efﬁcient
selection of transformed cells.
Generation of monoclonal antibody secreting
hybridomas
A synthetic peptide corresponding to residues 23–36 of human
CD20 with one additional cysteine at the N-terminus
(CMQSGPKPLFRRMSS) was synthesized. The peptide was
coupled with keyhole limpet hemocyanin. BALB/c mice were
primed with a subcutaneous injection of the keyhole limpet
hemocyanin-conjugated synthetic peptide emulsiﬁed in
Freund’s complete adjuvant. Mice were boosted four times at
two-week intervals with the same antigen. Mice that developed
antibodies as measured by enzyme-linked immunosorbent assay
with the immunizing peptide were boosted intravenously with
the same peptide 4 days before splenocytes were harvested and
fused to mouse myeloma cells. Hybridization and cloning were
performed according to standard procedures.
5
CD20 gene sequencing
Pleural effusion mononuclear cells were obtained by density
gradient centrifugation using Ficoll-Hypaque 1.077 (Sigma,
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underwent negative immunomagnetic selection using a B Cell
Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany)
for purifying B-linage cells. Total RNA was prepared using
TRIzol reagent according to the instructions of the manufacturer
(Invitrogen, Carlsbad, CA, USA) and 1mg was subjected to
reverse transcription under MMLV reverse transcriptase
(Takara). To prepare cDNA-containing whole coding region of
CD20, PCR ampliﬁcation was performed from 2ml of cDNA
using primers outside of the start and the stop codon: hCD20-50-
FW (50-GCAGCTAGCATCCAAATCAG-30) and hCD20-30-RV
(50-TGGTGCGTATGTGCAGAGTA-30). To determine the se-
quence of the CD20, we performed cycle sequencing on a
3130 DNA analyzer (Applied Biosystems, Foster City, CA, USA),
directly from PCR-puriﬁed products, in both directions using a
BigDye Terminator Cycle Sequencing Kit v3.1 (Applied Biosystems).
Immunocytochemistry
Cells were stained by rituximab and L26 antibody (DAKO,
Carpentaria, CA, USA) sequentially. Brieﬂy, the cells were
labeled by incubating in 10mg/ml of rituximab conjugated with
Alexa Fluor 647 (Invitrogen) according to previously described
procedure
6 and washed twice with phosphate-buffered saline.
Rituximab-labeled cells were swelled by treatment with 75mM
KCl and then were made to adhere onto collagen I-coated cover
glass by brief centrifugation. After ﬁxing and permeabilization,
the specimens were exposed to L26 antibody. Subsequently, the
specimens were washed and were incubated in Alexa488-
conjugated goat anti-mouse IgG. Nuclear staining was per-
formed using 5mg/ml of 4’-6-diamidino-2-phenylindole. The
preparations were screened for ﬂuorescence with a confocal
microscope (FV1000, OLYMPUS, Tokyo, Japan) using excitation
wavelengths of 405, 488 and 633nm to detect emission by
nuclear staining (4’-6-diamidino-2-phenylindole), rituximab or
L26 staining, respectively.
Immunohistochemistry
The tissues had been routinely ﬁxed in 10% neutral formalin and
embedded in parafﬁn. L26 antibody and monoclonal antibodies
raised against the N-terminal cytoplasmic region of CD20 were
used. The sections were deparafﬁnized and rehydrated in graded
alcohol. For heat-induced epitope retrieval, the sections were
subjected to Target Retrieval Solution, pH 9 (DAKO) at 971C for
40min. The sections then were brought to an automated stainer
(DAKO) by following the vendor’s protocol. EnVision Plus
(DAKO) and peroxidase detection methods were used.
Rituximab-binding analysis
Rituximab-binding analysis was performed according to our
previously developed imaging-based procedure, with some
modiﬁcations.
6 Brieﬂy, approximately ten thousands cells of
puriﬁed living lymphoma cells using a Dead cell removal kit
(Miltenyi Biotec) were incubated with 10mg/ml of anti-
CD19mAb labeled with Alexa Fluor 488 (Invitrogen) and
rituximab labeled with Alexa Fluor 647 (Invitrogen) for 30min
at 41C. The cells were washed with phosphate-buffered saline
two times and were then suspended in 4ml of RPMI1640
medium supplemented with 10% fetal bovine serum and 5mg/
ml of Hoechist 33342. The cell suspension was pipetted into a
well made of silicon, 2.5mm in diameter and 2mm in depth, on
a piece of cover glass. Images were collected by means of an
OLYMPUS PlanApo  60 oil objective in an OLYMPUS
FV-1000 confocal microscope (OLYMPUS). The ﬂuorophore
was excited by laser at 405, 488 or 633nm. The cells were
optically sectioned along the z-axis, and the images were
collected at 640 640 pixel resolution in a sequential mode to
minimize the crossover between channels. The step size in the
z-axis was 0.5mm. For three-dimensional reconstruction, two-
dimensional confocal stacks were saved in an Olympus.oib
format and three-dimensional images were generated using
Fluoview software (OLYMPUS).
Cell sorting and genetic analysis
The cryopreserved B-linage cells of the pleural effusion at
relapse were further sorted into two fractions of the cells with
high afﬁnity to rituximab (R-high) and those of low (R-low) by
using ﬂow cytometry (FACSvantage, Becton Dickinson, Franklin
Lakes, NJ, USA). The cells were labeled with rituximab
conjugated with AlexaFluor488 (Invitrogen) and anti-CD19-PE
(Becton Dickinson), then resuspended in phosphate-buffered
saline containing 2mg/ml of 7-AAD (Sigma) to exclude dead
cells. The sorting gate used for ‘R-high’ was rituximab
high/
CD19
þ/7-AAD
 , and for ‘R-low’ was rituximab
low/CD19
þ/7-
AAD
 . The sorted cells were immediately used for extraction of
both genomic DNA and total RNA using QIAamp DNA micro
kit and RNeasy micro kit, respectively, (QIAGEN, Hilden,
Germany). For amplifying the DNA-containing exon 8 of CD20
from genomic DNA, PCR was carried out using the forward
primer (50-TTCTGTTTTZGAACATAGTTCTCCCTGTCCA-30) and
the reverse primer (50-CAGAAAACAGAAATCACTTAAGGAGAG-30).
RT-PCR to amplify the CD20 cDNA were performed according
to the method described above. The PCR and RT-PCR products
were used to determine the CD20 gene sequence by direct
sequencing method. In addition, 1ml of RT-PCR products were
cloned into a TA-cloning vector (pCR2.1, Invitrogen) and CD20
DNA sequences of 16 clones of each RT-PCR product were
determined for estimating the ratio of different sequences.
Results
To conﬁrm the epitope of L26, we made a series of constructs of
the CD20 molecules with deletion mutations in the C-terminal
cytoplasmic domain and introduced them into retrovirus vectors
(Figure 1a). KMS12PE cells, in which expression of CD20 is not
detected immunohistologically, were then transformed, and we
established six kinds of sub-lines with the various C-terminal
deletion mutations of CD20. A semi-quantitative RT-PCR
analysis using a primer set designed to amplify the CD20
N-terminal region indicated that no major difference was found
in CD20 messenger RNA (mRNA) expression of the six cell lines
(Figure 1b). We carried out immunocytochemical analysis using
L26 and ﬂuorescence-labeled rituximab against these six CD20-
expressing transfectants, along with a mock transfectant and Raji
cells as negative and positive controls, respectively. The cells
stained by L26 antibody were only those expressing wild type
(amino acid 1–297) and DM1 mutant (amino acid 1–281). On
the other hand, rituximab could bind to shorter CD20
molecules, such as DM2, DM3 or DM4, as well as to the
CD20 molecules recognized by L26 (Figure 1c). These results
indicate that L26 antibody recognizes the C-terminal cytoplasm
region of CD20 molecules and that its epitope is present in the
amino-acid sequence of 264–281. The data suggest that
immunohistochemistry using L26 antibody will exhibit a false
negative if a deletion or a frame shift occurs upstream of this
epitope. In addition, the shortest deletion mutant DM5 that
lacked the C-terminal cytoplasmic region was detected by
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Blood Cancer Journalneither L26 antibody nor rituximab. Possible reasons might
include the low membrane localization of DM5 mutant and/or
low stability of the post-translational product. To clarify this, we
carried out western blot analysis using total cell lysate of the
series of deletion mutants that were tagged by FLAG peptide at
the N-terminal region of CD20 constructs. We found that the
cellular protein level of the DM5 deletion mutant of CD20 was
remarkably lower than that of others, suggesting that low post-
translational stability may be the reason for the low antigenicity
of DM5 mutant (data not shown).
To detect CD20 in the clinical specimens that acquired
rituximab resistance mutations, we developed novel anti-CD20
antibodies and screened them in parafﬁn sections. We isolated an
antibody speciﬁc for the CD20 N-terminus and named it CD20N.
Using this antibody, we carried out immunohistochemistry
c o n d u c t e do nt h eC D 2 0 - n e g a t i v ec a s e sb yL 2 6a n t i b o d y - b a s e d
analysis and found several cases with mutations in the C-terminal
cytoplasm region. Among them, a cell specimen, a part of which
had been cryopreserved as living cells, was included. This was
pleural effusion from a patient with relapsed diffuse large cell
B-cell lymphoma after complete remission following rituximab
containing chemotherapy (rituximab, cyclophosphamide, adria-
mycin, vincristine and prednisone). This patient did not respond to
further treatment with salvage therapies containing rituximab. The
results of immunochemical analysis of the ﬁbrin clot of the pleural
effusion at relapse, as well as the biopsy of lymph nodes at the ﬁrst
examination, are shown in Figure 2. The lymph node biopsy
before rituximab treatment was stained in the same way by both
L26 and CD20N antibodies. However, L26 antibody did not stain
at the population having mutated CD20 in the pleural effusion.
On the other hand, the CD20N antibody stained almost all of the
B-cell population. It should be noted that most of the cells were
stained at the region of plasma membrane by CD20N antibody.
As a result of DNA sequencing of puriﬁed B cells, we found
one nucleotide deletion mutation, which caused a frame
shift after the amino-acid residue 251, in half of the DNA
(Figure 3a). We conducted a binding analysis of rituximab using the
viable cells of B-lineage puriﬁed from cryopreserved mononuclear
cells. Most of these cells were CD19 positive. However, these cells
consisted of two kinds of cell populations that were quite different
in their afﬁnity for rituximab (Figure 3b). Furthermore, ﬂow
cytometry analysis revealed that the ﬂuorescent intensity of
ﬂuoro-labeled monoclonal antibody of CD20 decreased to less
than one-tenth in about half of the B-cell population (Figure 3c).
These results indicate that the C-terminal mutation of the CD20
gene in this case caused abnormality of extracellular-antigen
presentation, even though the protein expression and the cell
membrane localization seemed to be normal.
To reveal the genetic mechanisms of the reduced antigenicity
to rituximab, we conducted gene-sequencing analysis about
both population of cells that differ in afﬁnity to rituximab. The
cryopreserved B lymphocytes of the pleural effusion at relapse
were sorted into two fractions of cells of high afﬁnity to
rituximab (R-high) and those of low (R-low) by using ﬂow
cytometry (Figure 4a). Then genomic DNA and total RNA from
each fraction were extracted. The results of DNA sequencing of
exon 8 of CD20 in which the mutation was found demonstrated
that, surprisingly, both cell populations had both normal and
the monobasic deletion mutant CD20 genes. To determine
the proportion of the genes, the PCR-ampliﬁed DNA fragments
were inserted into a TA-cloning vector and 16 clones from both
‘R-high’ and ‘R-low’ fractions were determined the sequence of
CD20. As a result, the ratio of mutant DNA accounted for
approximately half of genomic DNA of both ‘R-high’ (7 out of 16)
and ‘R-low’ (9 out of 16). On the other hand, the results
of sequence analysis about the cDNA revealed that the ratio of
mutant mRNA in ‘R-low’ was remarkably increased (14 out of 16),
whereas that of ‘R-high’ was as the same of the results
of genomic DNA (8 out of 16; Figure 4b). We also carried out
a sequence analysis about genomic DNA from a slice of parafﬁn
-embedded tissue of lymph node at the ﬁrst diagnosis of this
patient, and found that approximately half of the genomic DNA
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Figure 1 Search for epitopic site of L26 antibody and analysis of the extracellular exposure of CD20 molecules having C-terminal deletion
mutation. (a) To explore the binding site of the L26 antibody, we constructed various lengths of the CD20 deletion mutant at their C-terminal
cytoplasmic domains. TM: transmembrane domain. (b) KMS12PE cells retrovirally transduced with C-terminal truncated CD20 showed
approximately similar levels of mRNA expression. (c) Immunocytochemical studies suggested that L26 recognizes amino-acid sequence between
264 and 281. An objective lens of  60 was used with a  10 digital zoom, bar: 5mm. DAPI, 4’-6-diamidino-2-phenylindole; DIC, differential
interference contrast; G3PDH, glyceraldehyde-3-phosphate dehydrogenase; WT, wild type.
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Blood Cancer Journalincluded the mutant CD20 gene same as the cells at relapse
(8 out of 16; Figure 4c). These results indicated that this patient
had already carried the mutation in CD20 gene, as onset of
primary lymphoma, and that a transcriptional imbalance
of wild-type CD20 and mutated CD20 have occurred by
undetermined mechanisms in some cell populations.
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rituximab bound markedly to approximately half of the cells, but the binding to the rest of cells could not be detected. The blue pseudo-color
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Figure 2 Immunohistochemistry (IHC) was performed on a biopsied specimen of a lymph node at the ﬁrst examination (a, b and c) and on a ﬁbrin
clot from the B-cell population from pleural effusion at the relapse phase (d, e and f). Both L26 and CD20N antibodies uniformly stained the
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images of the region boxed in (a–f) were shown in (a0–f0), respectively. An objective lens of  60 was used, bar: 50mm. PE lymphoma, lymphoma
cell in pleural effusion.
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7
mutated CD20 may affect also wild-type peptide in the same
cell. To verify this possibility, we introduced the CD20 gene
carrying the same mutation as this patient to CD20
  cell line,
KMS12PE and CD20
þ Daudi using a retrovirus vector, then
selected the cells expressing the exogeneous CD20 by a green
ﬂuorescent protein reporter promoted by an internal ribosome
entry site (Figure 5a). As the result of evaluating the binding
afﬁnity to rituximab by ﬂow cytometry, the exogeneous mutated
CD20 exhibited remarkably attenuated antigenicity to rituximab
as compared with the wild-type CD20 (Figure 5b). Next,
we transformed Daudi cells with the mutant CD20 to examine
the effect on expression of wild-type CD20 molecules.
In consideration of turnover of intrinsic CD20, we evaluated
binding of rituximab to the transfectants 7 days after virus
infection. As shown in Figure 5c, the expression of this mutated
CD20 was found to have hardly affected the afﬁnity for
rituximab. These results suggested that at least the mutation
found in this patient did not exert a dominant negative effect
against normal CD20 molecules.
Discussion
Previously, we reported that mutations in the CD20 gene were
found with some frequency in patients treated with rituximab.
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Figure 4 The genetic analysis of patient’s lymphoma cells. The cryopreserved B linage cells of the pleural effusion at relapse were further sorted
into two fractions of cells with high afﬁnity to rituximab (R-high) and those of low (R-low) by using ﬂow cytometry. (a) Dot blot of the cells before
and after sorting. (b) The results of CD20 sequence analysis of genomic DNA and cDNA of ‘R-high’ and ‘R-low’. The diagrams of direct sequencing
of CD20 exon 8 region are shown. The ratio of mutant and wild-type CD20 genes were determined by the sequencing of 16 clones of RT-PCR
products. (c) The results of genomic DNA sequence of primary lymphoma.
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Blood Cancer JournalThese cases often have a diagnosis of CD20 negative by
immunostaining, based on the commonly used L26 antibody,
and are difﬁcult to distinguish from the cases in which protein
expression of CD20 is extremely low. So the mutation in the
CD20 gene has been less noticed with regard to resistance to
rituximab. In the present study, we roughly identiﬁed the
epitope of L26, and it became clear that all of the C-terminal-
mutated CD20 that we had found earlier lost the epitope for
L26, because the epitope was located near the C-terminal of
CD20 molecule. To detect CD20 with these mutations
comprehensively, we developed monoclonal antibodies that
recognize a part of the amino-acid sequence of the N-terminal
cytoplasmic region of CD20. One of these antibodies, CD20N,
recognized CD20 proteins, including those having a mutation
in the parafﬁn-embedded, formalin-ﬁxed specimen. In this
study, we showed that it could be applied to the primary
screening of the lymphoma cells that express mutated CD20 by
selecting L26-negative and CD20N-positive cells.
To date, there are not many reports that the mutation of the
CD20 gene contributes to resistance to rituximab.
1,8 A part of
the reason for this may be that L26 cannot detect most of
mutated CD20. In addition, Johnson et al.
8 carried out a
sequencing screening of exon 5 of the CD20 gene encompass-
ing the epitope of rituximab. They detected CD20 mutations
involving the rituximab epitope in only 1/264 (0.4%) and 1/15
(6%) of the biopsies taken at diagnosis and relapse, respectively.
Similarly, in our previous screening, no mutation was found in
the region of exon 5, whereas four cases with mutation (out of
50) were found in the C-terminal cytoplasm region of CD20.
1
In the CD20 gene, a genetic mutation could be more likely to
occur in the C-terminal region compared with around the region
of rituximab epitope by uncertain mechanism(s).
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Figure 5 The effect of mutant CD20 on wild-type CD20 with respect to rituximab binding. (a) The schematic diagram of retrovirus vectors used
for transduction of wild-type and mutant CD20.( b) The transfectants were labeled with PE-conjugated. rituximab and analyzed by ﬂow cytometry
at seven days after viral infection. The contour plots of KMS12PE cells transfected with wild-type (upper panel) or mutated CD20 (lower panel) are
shown. (c) Daudi cells were transfected with mutated CD20 and analyzed the rituximab-binding. The mutant CD20 introduced exogenously
hardly affected the binding of rituximab to Daudi cells. IRES, internal ribosome entry site; LTR, long terminal repeat; wt, wild type; mt, mutant.
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identiﬁed case with the mutation in the CD20 gene, we
successfully analyzed in detail the phenotype of lymphoma
cells having mutated CD20. In this case, a frame shift mutation
occurred because of one base nucleotide deletion, resulting in
the translation of peptide of another reading frame of 41 amino
acids after the amino acid position 250 with a slight early
termination. Immunohistochemical analysis using CD20N anti-
body revealed that the CD20 molecules with C-terminal
mutations were indeed expressed in the lymphoma cells, and
located at the cell membrane. However, the living cell binding
evaluation showed that rituximab could scarcely bind to these
cells. These results suggest that the C-terminal region of CD20
undertakes a critical role in presentation of the large loop in
which the rituximab-binding site locates.
As a result of genetic analysis for lymphoma cells, it was
suggested that this patient had a mutation in the CD20 gene as
onset of primary lymphoma. Because normal and mutated
CD20 gene were almost the same copy numbers and the most of
cells in the lymph follicle were stained in L26 at the ﬁrst
diagnosis, it can be considered that the lymphoma cells of this
patient had equal number of normal and mutated CD20 alleles
rather than the mixture of the cells having only normal CD20
allele(s) or only mutant allele(s). And at the relapse, two
cell populations of the different afﬁnity for rituximab has arose
(‘R-high’ and ‘R-low’), and both had a genome of the same
mutation status, however, the expression of the mutated mRNA
has been predominant only in ‘R-low’. As a result of semi-
quantitative RT-PCR analysis revealed that whole CD20 mRNA
expression of ‘R-low’ slightly decreased as compared with that
of ‘R-high’ (data not shown), the imbalanced mRNA expression
in ‘R-low’ may be due to the suppression of CD20 mRNA
expression from the wild-type allele at the transcription level.
To summarize these data, the primary lymphoma cells of this
patient expressed both wild-type and mutated CD20 equally. As
the mutant CD20 in this case was found to have little effect on
the antigenicity of wild-type CD20 molecules, these cells were
still susceptible to rituximab plus CHOP and the patient has
obtained complete remission. However, at the relapse, cells that
predominantly expressed the mutant CD20 emerged. This
mutant molecule expressed and localized at the plasma
membrane, however, the large loop could not be oriented
appropriately. So it was considered that rituximab-containing
salvage treatments have failed perhaps because afﬁnity for
rituximab was not enough.
It was noteworthy that the antibody that recognizes N-terminal
region of CD20 has capability to detect the mutated CD20 before
start of the salvage therapy. This indicated the possibility that we
can predict the existence of lymphoma cells resistant to rituximab
before start of therapy. In addition, this information may provide
important criterion to judge whether it should switch to the
treatment such as using second-generation CD20 antibody that is
effective against fewer CD20-expressing cells
9–12 or using anti-
body for the different target molecule such as CD22.
13,14
The resistance for a molecular target drug acquired by a
mutation in the gene of the target molecule is commonly
considered to be irreversible.
15–19 We propose here that detecting
a mutation in the gene by screening using antibodies of two kinds
of epitope is useful in detection of irreversible resistant mutation for
molecular targeted drug including rituximab.
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